STERIS (STE) Competitors

$201.95 -5.50 (-2.65%)

Closing price 03:59 PM Eastern

Extended Trading

$204.25 +2.30 (+1.14%)

As of 07:50 PM Eastern

STE vs. BSX, EW, IDXX, BDX, and RMD

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), and ResMed (RMD). These companies are all part of the "health care equipment" industry.

How does STERIS compare to Boston Scientific?

STERIS (NYSE:STE) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

STERIS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

94.7% of STERIS shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

STERIS presently has a consensus target price of $275.20, indicating a potential upside of 36.27%. Boston Scientific has a consensus target price of $93.91, indicating a potential upside of 76.10%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Boston Scientific	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Boston Scientific had 2 more articles in the media than STERIS. MarketBeat recorded 25 mentions for Boston Scientific and 23 mentions for STERIS. STERIS's average media sentiment score of 0.80 beat Boston Scientific's score of 0.66 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Boston Scientific	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.46B	3.63	$614.64M	$7.17	28.17
Boston Scientific	$20.07B	3.95	$2.90B	$2.39	22.31

Boston Scientific has a net margin of 17.29% compared to STERIS's net margin of 12.15%. Boston Scientific's return on equity of 19.17% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	12.15%	14.34%	9.58%
Boston Scientific	17.29%	19.17%	10.77%

Summary

Boston Scientific beats STERIS on 11 of the 17 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

STERIS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.46B	3.63	$614.64M	$7.17	28.17
Edwards Lifesciences	$6.07B	7.32	$1.07B	$1.88	41.02

Edwards Lifesciences has a net margin of 17.39% compared to STERIS's net margin of 12.15%. Edwards Lifesciences' return on equity of 15.19% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	12.15%	14.34%	9.58%
Edwards Lifesciences	17.39%	15.19%	11.71%

94.7% of STERIS shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

STERIS presently has a consensus target price of $275.20, indicating a potential upside of 36.27%. Edwards Lifesciences has a consensus target price of $95.65, indicating a potential upside of 24.04%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79

In the previous week, STERIS had 12 more articles in the media than Edwards Lifesciences. MarketBeat recorded 23 mentions for STERIS and 11 mentions for Edwards Lifesciences. STERIS's average media sentiment score of 0.80 beat Edwards Lifesciences' score of 0.73 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Edwards Lifesciences beats STERIS on 10 of the 17 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

IDEXX Laboratories has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, STERIS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

IDEXX Laboratories has higher earnings, but lower revenue than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	9.75	$1.06B	$13.58	39.18
STERIS	$5.46B	3.63	$614.64M	$7.17	28.17

In the previous week, IDEXX Laboratories had 9 more articles in the media than STERIS. MarketBeat recorded 32 mentions for IDEXX Laboratories and 23 mentions for STERIS. IDEXX Laboratories' average media sentiment score of 0.94 beat STERIS's score of 0.80 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	15 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories currently has a consensus target price of $751.00, suggesting a potential upside of 41.17%. STERIS has a consensus target price of $275.20, suggesting a potential upside of 36.27%. Given IDEXX Laboratories' higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 12.15%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
STERIS	12.15%	14.34%	9.58%

Summary

IDEXX Laboratories beats STERIS on 12 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Becton, Dickinson and Company currently has a consensus target price of $184.86, suggesting a potential upside of 29.17%. STERIS has a consensus target price of $275.20, suggesting a potential upside of 36.27%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Becton, Dickinson and Company has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, STERIS has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

STERIS has a net margin of 12.15% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
STERIS	12.15%	14.34%	9.58%

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.9%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 35.1% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 53 consecutive years and STERIS has raised its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.81	$1.68B	$3.95	36.23
STERIS	$5.46B	3.63	$614.64M	$7.17	28.17

In the previous week, Becton, Dickinson and Company had 11 more articles in the media than STERIS. MarketBeat recorded 34 mentions for Becton, Dickinson and Company and 23 mentions for STERIS. STERIS's average media sentiment score of 0.80 beat Becton, Dickinson and Company's score of 0.65 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	11 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

STERIS beats Becton, Dickinson and Company on 11 of the 19 factors compared between the two stocks.

How does STERIS compare to ResMed?

STERIS (NYSE:STE) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

STERIS currently has a consensus target price of $275.20, suggesting a potential upside of 36.27%. ResMed has a consensus target price of $286.18, suggesting a potential upside of 43.90%. Given ResMed's stronger consensus rating and higher probable upside, analysts clearly believe ResMed is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

STERIS has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, ResMed has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

ResMed has a net margin of 27.44% compared to STERIS's net margin of 12.15%. ResMed's return on equity of 25.35% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	12.15%	14.34%	9.58%
ResMed	27.44%	25.35%	18.69%

94.7% of STERIS shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. STERIS pays out 35.1% of its earnings in the form of a dividend. ResMed pays out 23.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and ResMed has increased its dividend for 13 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has lower revenue, but higher earnings than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.46B	3.63	$614.64M	$7.17	28.17
ResMed	$5.15B	5.63	$1.40B	$10.37	19.18

In the previous week, STERIS had 11 more articles in the media than ResMed. MarketBeat recorded 23 mentions for STERIS and 12 mentions for ResMed. ResMed's average media sentiment score of 0.98 beat STERIS's score of 0.80 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats STERIS on 12 of the 20 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$20.35B	$7.02B	$6.24B	$22.90B
Dividend Yield	1.21%	1.72%	2.78%	4.03%
P/E Ratio	28.17	48.63	20.87	28.90
Price / Sales	3.63	56.28	554.17	25.35
Price / Cash	14.55	25.20	27.81	19.21
Price / Book	3.00	6.48	9.77	4.65
Net Income	$614.64M	$158.34M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-9.21%	5.79%	6.28%	3.95%
1 Year Performance	-10.85%	-1.68%	41.80%	28.96%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.5664 of 5 stars	$201.95 -2.7%	$275.20 +36.3%	-8.4%	$20.35B	$5.46B	28.17	17,787	Trending News Earnings Report Dividend Announcement
BSX Boston Scientific	4.6088 of 5 stars	$56.96 +0.8%	$93.91 +64.9%	-47.6%	$83.97B	$20.07B	23.83	59,000	Analyst Revision
EW Edwards Lifesciences	4.4682 of 5 stars	$83.32 -0.8%	$95.65 +14.8%	+8.2%	$48.42B	$6.07B	44.32	16,000	Positive News
IDXX IDEXX Laboratories	4.3797 of 5 stars	$563.12 -0.8%	$751.00 +33.4%	+13.9%	$45.07B	$4.30B	43.08	11,000	Earnings Report
BDX Becton, Dickinson and Company	4.9106 of 5 stars	$146.30 -2.0%	$186.57 +27.5%	-10.8%	$42.51B	$21.84B	23.87	72,000	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to ResMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Which has more risk and volatility, STE or BSX?

Do institutionals & insiders have more ownership in STE or BSX?

Do analysts recommend STE or BSX?

Does the media prefer STE or BSX?

Which has stronger valuation & earnings, STE or BSX?

Is STE or BSX more profitable?

Summary

How does STERIS compare to Edwards Lifesciences?

Which has more risk and volatility, STE or EW?

Which has stronger valuation & earnings, STE or EW?

Is STE or EW more profitable?

Do institutionals & insiders have more ownership in STE or EW?

Do analysts recommend STE or EW?

Does the media prefer STE or EW?

Summary

How does STERIS compare to IDEXX Laboratories?

Which has more risk and volatility, IDXX or STE?

Which has better earnings & valuation, IDXX or STE?

Does the media refer more to IDXX or STE?

Do analysts rate IDXX or STE?

Do institutionals and insiders have more ownership in IDXX or STE?

Is IDXX or STE more profitable?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Do analysts rate BDX or STE?

Which has more risk & volatility, BDX or STE?

Is BDX or STE more profitable?

Do insiders and institutionals have more ownership in BDX or STE?

Is BDX or STE a better dividend stock?

Which has preferable valuation and earnings, BDX or STE?

Does the media refer more to BDX or STE?

Summary

How does STERIS compare to ResMed?

Do analysts rate STE or RMD?

Which has more volatility & risk, STE or RMD?

Is STE or RMD more profitable?

Do institutionals and insiders hold more shares of STE or RMD?

Is STE or RMD a better dividend stock?

Which has better valuation & earnings, STE or RMD?

Does the media prefer STE or RMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools